Data updated: Jun 28, 2026
Vitiligo Clinical Trial Landscape
Vitiligo is being studied across 113 clinical trials registered since 2008, with 48 programs currently active. The competitive pipeline includes 14 active Phase 3 trials, 20 active Phase 2 trials, and 7 active Phase 1 trials.
Top industry sponsors include Incyte Corporation, Pfizer, Jiangsu HengRui Medicine Co., Ltd..
Trial activity
48 active / 113 total since 2008
Active by phase 14 Ph3 / 32 20 Ph2 / 53 7 Ph1 / 12 7 Ph4 / 16
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Incyte Corporation 4 8 0
Pfizer 2 2 0
Jiangsu HengRui Medicine Co., Ltd. 2 0 0
AbbVie 1 1 0
Takeda 1 0 0
Dren Bio 1 0 0
Novartis 1 0 0
Shanghai Longwood Biopharmaceuticals Co., Ltd. 1 0 0
Innovent Biologics (Suzhou) Co. Ltd. 1 0 0
Eli Lilly 1 0 0
Elixiron Immunotherapeutics (Hong Kong) Ltd. 1 0 0
Hudson Biotech 1 0 0
Teva Branded Pharmaceutical Products R&D LLC 1 0 0
CAGE Bio Inc. 1 0 0
Jiangsu vcare pharmaceutical technology co., LTD 1 0 0
How the field has grown
New-trial starts peaked in 2025 (18 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (22 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 4
2017 3
2018 2
2019 5
2020 4
2021 8
2022 6
2023 10
2024 10
2025 18
2026 17
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (1) 42
2017 (0) 0
2018 (0) 0
2019 (3) 330
2020 (2) 267
2021 (0) 0
2022 (2) 324
2023 (5) 467
2024 (3) 50
2025 (3) 250
2026 (3) 20
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT06163326 ACTIVE NOT RECRUITING
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Pfizer n=394
NCT07557693 NOT YET RECRUITING
Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo
Centre Hospitalier Universitaire de Nice n=5
NCT07509242 NOT YET RECRUITING
Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study
Yohanes Firmansyah, dr, MH, MM n=150
NCT06113471 ACTIVE NOT RECRUITING
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Incyte Corporation n=450
NCT06072183 ACTIVE NOT RECRUITING
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
Pfizer n=1,571
NCT06113445 ACTIVE NOT RECRUITING
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Incyte Corporation n=467
NCT06548360 RECRUITING
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation n=180
NCT06804811 RECRUITING
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Incyte Corporation n=250
NCT06118411 ACTIVE NOT RECRUITING
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie n=614
NCT07047612 RECRUITING
ICP-332 in Subjects With Non-segmental Vitiligo
Beijing InnoCare Pharma Tech Co., Ltd. n=603
NCT06109649 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
Clinuvel, Inc. n=200
NCT06719024 RECRUITING
Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Hospital Authority, Hong Kong n=20
NCT07595939 NOT YET RECRUITING
Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo
The Children's Hospital of Zhejiang University School of Medicine n=20
NCT05583526 COMPLETED
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
Pfizer n=607
NCT04057573 COMPLETED
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Incyte Corporation n=344
NCT04052425 COMPLETED
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
Incyte Corporation n=330
NCT04530344 COMPLETED
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Incyte Corporation n=458
NCT04942860 COMPLETED
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo
Nicolaus Copernicus University n=25
NCT05513924 COMPLETED
Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.
South Valley University n=40
NCT04774809 TERMINATED
Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
Reistone Biopharma Company Limited n=75
NCT02466997 COMPLETED
Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC
University Hospital, Bordeaux n=42
NCT02156427 COMPLETED
Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism
Laboratoires Genévrier n=38
NCT02191748 TERMINATED
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
Rutgers, The State University of New Jersey n=22
NCT01822379 WITHDRAWN
Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo
Henry Ford Health System
NCT00631865 COMPLETED
Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin
Royan Institute n=300
NCT01419964 WITHDRAWN
Efficacy and Safety of ACH24 in the Treatment of Vitiligo
Ache Laboratorios Farmaceuticos S.A.
NCT01841008 TERMINATED
Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control
Centre Hospitalier Universitaire de Nice n=35
NCT01629979 COMPLETED
Epidermal Cell Transplantation in Vitiligo Skin
Centre Hospitalier Universitaire de Nice n=23
NCT01087216 COMPLETED
Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo
Centre Hospitalier Universitaire de Nice n=20
NCT00696358 COMPLETED
Excimer Lamp Versus Excimer Laser in Vitiligo Treatment
Centre Hospitalier Universitaire de Nice
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only